Program
ALK Molecular Glue Degrader TRI-611
Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by TRIANA Biomedicines.
Furthest: phase 2, since Mar 11, 20261 company-led study, 1 open or runningNext primary completion: May 31, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TRIANA Biomedicines | 11 open or running | phase 2since Mar 11, 2026 | Mar 11, 2026 | May 31, 2029phase 2 · NCT07491497 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2026First study: phase 2 study in ALK-positive NSCLCFirst studyNCT07491497 · 160 planned · United States, Australia, France and more
Ahead
- May 31, 2029Primary completion: phase 2 study in ALK-positive NSCLCNCT07491497
TargetBeta
ALK →read by rule
“An orally bioavailable, central nervous system (CNS) penetrant molecular glue degrader (MGD) of the receptor tyrosine kinase (RTK) anaplastic lymphoma kinase (ALK), ”NCIt, by rule
Other programs on ALK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Crizotinibrule | Pfizer | phase 4 | 31 |
| lorlatinibrule | Pfizer | phase 4 | 20 |
| gilteritinibrule | Astellas Pharma | phase 3 | 20 |
| ensartinibrule | Betta Pharmaceuticals | phase 3 | 12 |
| repotrectinibrule | Bristol-Myers Squibb | phase 3 | 9 |
| neladalkib | GlaxoSmithKline | phase 3 | 2 |
| Foritinib Succinate | Fosun Pharma | phase 2 | 1 |
| AQUA07 | Hoffmann-La Roche | phase 1 | 1 |
| SIM0518rule | Simcere Pharmaceutical Group | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07491497ALK-positive NSCLC · United States, Australia, France and more | 2 | Recruiting | May 31, 2029 | 160 |
How it is read
Names in the registry
- “TRI-611”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.